Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences (RNA) Shares Issued (2019 - 2025)

Avidity Biosciences (RNA) has disclosed Shares Issued for 7 consecutive years, with -$18.7 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Shares Issued fell 102.57% year-over-year to -$18.7 million, compared with a TTM value of $744.6 million through Sep 2025, up 1843.39%, and an annual FY2024 reading of $762.2 million, up 35732.68% over the prior year.
  • Shares Issued was -$18.7 million for Q4 2025 at Avidity Biosciences, down from $18.7 million in the prior quarter.
  • Across five years, Shares Issued topped out at $726.0 million in Q4 2024 and bottomed at -$105.2 million in Q3 2024.
  • Average Shares Issued over 5 years is $45.1 million, with a median of $301000.0 recorded in 2021.
  • Peak annual rise in Shares Issued hit 34031.26% in 2024, while the deepest fall reached 7490.62% in 2024.
  • Year by year, Shares Issued stood at $1.5 million in 2021, then tumbled by 6957.79% to -$101.7 million in 2022, then skyrocketed by 102.09% to $2.1 million in 2023, then skyrocketed by 34031.26% to $726.0 million in 2024, then tumbled by 102.57% to -$18.7 million in 2025.
  • Business Quant data shows Shares Issued for RNA at -$18.7 million in Q4 2025, $18.7 million in Q3 2025, and $726.0 million in Q4 2024.